RDIF and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India
16 September 2020 - 12:26PM
Business Wire
The Russian Direct Investment Fund (RDIF), Russia’s sovereign
wealth fund, and Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), a
global pharmaceutical company headquartered out of India, have
agreed to cooperate on clinical trials and distribution of Sputnik
V vaccine in India. Upon regulatory approval in India, RDIF shall
supply to Dr. Reddy’s 100 million doses of the vaccine. The Sputnik
V vaccine, which is based on well-studied human adenoviral vector
platform with proven safety, is undergoing clinical trials for the
coronavirus pandemic. Deliveries could potentially begin in late
2020 subject to completion of successful trials and registration of
the vaccine by regulatory authorities in India.
The agreement between RDIF and Dr Reddy’s reflects the growing
awareness of countries and organizations to have a diversified
anti-COVID vaccine portfolio to protect their populations.
Kirill Dmitriev, CEO of the Russian Direct Investment
Fund, said, “We are very pleased to partner with Dr. Reddy’s in
India. Dr. Reddy’s has had a very well established and respected
presence in Russia for over 25 years and is one of the leading
pharmaceutical companies in India. India is amongst the most
severely impacted countries from COVID 19 and we believe our human
adenovirus dual vector platform will provide a safe and
scientifically validated option to India in the battle against
COVID 19. RDIF partners will receive an effective and safe drug to
fight the coronavirus. The platform of human adenoviral vectors,
which is the core of the Russian vaccine, has been tested in more
than 250 clinical studies over decades, and it has been found safe
with no potential negative long-term consequences.”
G V Prasad, Co-Chairman & Managing Director of Dr.
Reddy’s Laboratories said, “We are pleased to partner with RDIF
to bring the vaccine to India. The Phase I and II clinical trials
have shown promising results. We will be conducting Phase-III
trials in India to ensure safety and efficacy for the Indian
population and to meet the requirements of the Indian regulators.
Sputnik V vaccine could provide a credible option in our fight
against COVID 19 in India.”
Prof. Sergey Tsarenko, Deputy Chief Physician for
Anesthesiology and Reanimation at Hospital No. 52 in Moscow,
said, “The main criteria for evaluating a vaccine are safety and
efficacy. In Sputnik V, safety is ensured by the use of human
adenoviral vectors, which we repeatedly encounter throughout our
lives. Efficacy is achieved by using two different human
adenoviruses sequentially, which differentiates this platform.”
On August 11, the Sputnik V vaccine developed by the Gamaleya
National Research Institute of Epidemiology and Microbiology was
registered by the Ministry of Health of Russia and became the
world’s first registered vaccine against COVID-19 based on the
human adenoviral vectors platform. Detailed information on the
Sputnik V vaccine, the technological platform of human adenoviral
vectors, and other details are available at sputnikvaccine.com.
On September 4, a research paper on the results of Phase I and
Phase II clinical trials of the Sputnik V vaccine was published in
The Lancet, one of the leading international medical journals,
demonstrating no serious adverse effects and a stable immune
response in 100% of participants. Post-registration clinical trials
of the Sputnik V vaccine involving 40,000 volunteers are currently
ongoing. More than 55,000 volunteers have applied to take part in
post-registration trials. The first results of these trials are
expected to be published in October-November 2020.
Russian Direct Investment Fund (RDIF) is Russia's
sovereign wealth fund established in 2011 to make equity
co-investments, primarily in Russia, alongside reputable
international financial and strategic investors. RDIF acts as a
catalyst for direct investment in the Russian economy. RDIF’s
management company is based in Moscow. Currently, RDIF has
experience of the successful joint implementation of more than 80
projects with foreign partners totaling more than RUB1.9 tn and
covering 95% of the regions of the Russian Federation. RDIF
portfolio companies employ more than 800,000 people and generate
revenues which equate to more than 6% of Russia’s GDP. RDIF has
established joint strategic partnerships with leading international
co-investors from more than 18 countries that total more than $40
bn. Further information can be found at www.rdif.ru.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200916005450/en/
Arseniy Palagin Russian Direct Investment Fund Press
Secretary Tel: +7 495 644 34 14, ext. 2395 Mobile: +7 916 110 31 41
E-mail: arseniy.palagin@rdif.ru
Andrew Leach / Maria Shiryaevskaya Hudson Sandler Tel:
+44 (0) 20 7796 4133
Dr. Reddy’s Laboratories Ltd. Amit Agarwal, Investor
Relations Tel: +91-40-49002135 E-mail: amita@drreddys.com
Aparna Tekuri, Media Relations Tel: +91-40- 49002446
E-mail: aparnatekuri@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024